|
1
|
Swerdlow SH, Campo E, Harris NL, Jaffe ES,
Pileri SA and Stein H (eds): WHO Classification of Tumours of
Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, pp 291-297,
2017.
|
|
2
|
Yamamoto Y, Goto N, Takemura M, Yamasuge
W, Yabe K, Takami T, Miyazaki T, Takeuchi T, Shiraki M, Shimizu M,
et al: Association between increased serum GP88 (progranulin)
concentrations and prognosis in patients with malignant lymphomas.
Clin Chim Acta. 473:139–146. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Nakamura N, Hara T, Shibata Y, Matsumoto
T, Nakamura H, Ninomiya S, Kito Y, Kitagawa J, Kanemura N, Goto N,
et al: Sarcopenia is an independent prognostic factor in male
patients with diffuse large B-cell lymphoma. Ann Hematol.
94:2043–2053. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Nakamura N, Goto N, Tsurumi H, Takemura M,
Kanemura N, Kasahara S, Hara T, Yasuda I, Shimizu M, Sawada M, et
al: Serum level of soluble tumor necrosis factor receptor 2 is
associated with the outcome of patients with diffuse large B-cell
lymphoma treated with the R-CHOP regimen. Eur J Haematol.
91:322–331. 2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Goto N, Tsurumi H, Takemura M, Kanemura N,
Kasahara S, Hara T, Yasuda I, Shimizu M, Yamada T, Sawada M, et al:
Serum soluble CD27 level is associated with outcome in patients
with diffuse large B-cell lymphoma treated with rituximab,
cyclophosphamide, doxorubicin, vincristine and prednisolone. Leuk
Lymphoma. 53:1494–1500. 2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Goto N, Tsurumi H, Goto H, Shimomura YI,
Kasahara S, Hara T, Yasuda I, Shimizu M, Murakami N, Yoshikawa T,
et al: Serum soluble interleukin-2 receptor (sIL-2R) level is
associated with the outcome of patients with diffuse large B cell
lymphoma treated with R-CHOP regimens. Ann Hematol. 91:705–714.
2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ninomiya S, Hara T, Tsurumi H, Goto N,
Saito K, Seishima M, Takami T and Moriwaki H: Indoleamine
2,3-dioxygenase expression and serum kynurenine concentrations in
patients with diffuse large B-cell lymphoma. Leuk Lymphoma.
53:1143–1145. 2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Goto N, Tsurumi H, Kasahara S, Kanemura N,
Hara T, Yasuda I, Shimizu M, Murakami N, Sawada M, Yamada T, et al:
Serum interleukin-18 level is associated with the outcome of
patients with diffuse large B-cell lymphoma treated with CHOP or
R-CHOP regimens. Eur J Haematol. 87:217–227. 2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ninomiya S, Hara T, Tsurumi H, Hoshi M,
Kanemura N, Goto N, Kasahara S, Shimizu M, Ito H, Saito K, et al:
Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in
patients with diffuse large B-cell lymphoma treated with R-CHOP.
Ann Hematol. 90:409–416. 2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Yoshikawa T, Hara T, Tsurumi H, Goto N,
Hoshi M, Kitagawa J, Kanemura N, Kasahara S, Ito H, Takemura M, et
al: Serum concentration of L-kynurenine predicts the clinical
outcome of patients with diffuse large B-cell lymphoma treated with
R-CHOP. Eur J Haematol. 84:304–309. 2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hara T, Tsurumi H, Goto N, Kanemura N,
Yoshikawa T, Kasahara S, Yamada T, Sawada M, Goto H, Fukuno K, et
al: Serum soluble Fas level determines clinical outcome of patients
with diffuse large B-cell lymphoma treated with CHOP and R-CHOP. J
Cancer Res Clin Oncol. 135:1421–1428. 2009.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kojima Y, Tsurumi H, Goto N, Shimizu M,
Kasahara S, Yamada T, Kanemura N, Hara T, Sawada M, Saio M, et al:
Fas and Fas ligand expression on germinal center type-diffuse large
B-cell lymphoma is associated with the clinical outcome. Eur J
Haematol. 76:465–472. 2006.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Watanuki-Miyauchi R1, Kojima Y, Tsurumi H,
Hara T, Goto N, Kasahara S, Saio M, Moriwaki H and Takami T:
Expression of survivin and of antigen detected by a novel
monoclonal antibody, T332, is associated with outcome of diffuse
large B-cell lymphoma and its subtypes. Pathol Int. 55:324–330.
2005.PubMed/NCBI View Article : Google Scholar
|
|
14
|
International Non-Hodgkin's Lymphoma
Prognostic Factors Project. A predictive model for aggressive
non-Hodgkin's lymphoma. N Engl J Med. 329:987–994. 1993.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Sehn LH, Berry B, Chhanabhai M, Fitzgerald
C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J,
et al: The revised International Prognostic Index(R-IPI)is a better
predictor of outcome than the standard IPI for patients with
diffuse large B-cell lymphoma treated with R-CHOP. Blood.
109:1857–1861. 2007.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gorrini C, Harris IS and Mak TW:
Modulation of oxidative stress as an anticancer strategy. Nat Rev
Drug Discov. 12:931–947. 2013.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Salzman R, Pácal L, Kaňková K, Tomandl J,
Horáková Z, Tóthová E and Kostřica R: High perioperative level of
oxidative stress as a prognostic tool for identifying patients with
a high risk of recurrence of head and neck squamous cell carcinoma.
Int J Clin Oncol. 15:565–570. 2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Cesarone MR, Belcaro G, Carratelli M,
Cornelli U, De Sanctis MT, Incandela L, Barsotti A, Terranova R and
Nicolaides A: A simple test to monitor oxidative stress. Int
Angiol. 18:127–130. 1999.PubMed/NCBI
|
|
19
|
Trotti R, Carratelli M and Barbieri M:
Performance and clinical application of a new, fast method for the
detection of hydroperoxides in serum. Panminerva Med. 44:37–40.
2002.PubMed/NCBI
|
|
20
|
Hirose H, Kawabe H, Komiya N and Saito I:
Relations between serum reactive oxygen metabolites (ROMs) and
various inflammatory and metabolic parameters in a Japanese
population. J Atheroscler Thromb. 16:77–82. 2009.PubMed/NCBI View
Article : Google Scholar
|
|
21
|
Tsukioka T, Nishiyama N, Iwata T, Nagano
K, Tei K and Suehiro S: Preoperative serum oxidative stress marker
as a strong indicator of nodal involvement in clinical stage I lung
adenocarcinoma. Int J Clin Oncol. 17:250–255. 2012.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Miyazaki T, Takagi K, Mine M, Yamasaki N,
Tsuchiya T, Matsumoto K, Hatachi G, Izumino H, Doi R, Machino R and
Nagayasu T: Video-assisted thoracic surgery attenuates
perioperative oxidative stress response in lung cancer patients: A
preliminary study. Acta Med Nagasaki. 59:19–25. 2014.
|
|
23
|
Gencer M, Ceylan E, Aksoy N and Uzun K:
Association of serum reactive oxygen metabolite levels with
different histopathological types of lung cancer. Respiration.
73:520–524. 2006.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Suzuki Y, Imai K, Takai K, Hanai T,
Hayashi H, Naiki T, Nishigaki Y, Tomita E, Shimizu M and Moriwaki
H: Hepatocellular carcinoma patients with increased oxidative
stress levels are prone to recurrence after curative treatment: A
prospective case series study using the d-ROM test. J Cancer Res
Clin Oncol. 139:845–852. 2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sasaki Y: Does oxidative stress
participate in the development of hepatocellular carcinoma? J
Gastroenterol. 41:1135–1148. 2006.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Inokuma T, Haraguchi M, Fujita F, Tajima Y
and Kanematsu T: Oxidative stress and tumor progression in
colorectal cancer. Hepatogastroenterology. 56:343–347.
2009.PubMed/NCBI
|
|
27
|
Hou D, Liu Z, Xu X, Liu Q, Zhang X, Kong
B, Wei JJ, Gong Y and Shao C: Increased oxidative stress mediates
the antitumor effect of PARP inhibition in ovarian cancer. Redox
Biol. 17:99–111. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Nojima J, Motoki Y, Tsuneoka H, Kuratsune
H, Matsui T, Yamamoto M, Yanagihara M, Hinoda Y and Ichihara K:
‘Oxidation stress index’ as a possible clinical marker for the
evaluation of non-Hodgkin lymphoma. Br J Haematol. 155:528–530.
2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Jaffe ES, Harris NL, Stein H and Vardiman
JW: World Health Organization classification of tumors, pathology
and genetics tumors of haematopoietic and lymphoid tissues. IARC
Press, Lyon, pp 109-236, 2001.
|
|
30
|
Sugiura T, Dohi Y, Takase H, Yamashita S,
Tanaka S and Kimura G: Increased reactive oxygen metabolites is
associated with cardiovascular risk factors and vascular
endothelial damage in middle-aged Japanese subjects. Vasc Health
Risk Manag. 7:475–482. 2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kakita H, Hussein MH, Daoud GA, Kato T,
Murai H, Sugiura T, Mizuno K, Yamada Y, Ito T, Fukuda S, et al:
Total hydroperoxide and biological antioxidant potentials in a
neonatal sepsis model. Pediatr Res. 60:675–679. 2006.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Takagi T and Oguro M:
(2'-R)-4'-o-tetrahydropyranyladriamycin, a new anthracycline
derivative; its effectiveness in lymphoid malignancies. Cancer
Chemother Pharmacol. 20:151–154. 1987.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Miller AA and Salewski E: Prospects for
pirarubicin. Med Pediatr Oncol. 22:261–268. 1994.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Tsurumi H, Yamada T, Sawada M, Kasahara S,
Kanemura N, Kojima Y, Fukuno K, Hara T, Saio M, Takahashi T, et al:
Biweekly CHOP or THP-COP regimens in the treatment of newly
diagnosed aggressive non-Hodgkin's lymphoma. A comparison of
doxorubicin and pirarubicin: A randomized phase II study. J Cancer
Res Clin Oncol. 130:107–113. 2004.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Hara T, Tsurumi H, Goto N, Kitagawa J,
Kanemura N, Yoshikawa T, Kasahara S, Goto H, Fukuno K, Yamada T, et
al: Phase II study of Rituximab combined with THP-COP as first-line
therapy for patients younger than 70 years with diffuse large B
cell lymphoma. J Cancer Res Clin Oncol. 136:65–70. 2010.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Kasahara S, Hara T, Tsurumi H, Goto N,
Kitagawa J, Kanemura N, Yoshikawa T, Goto H, Fukuno K, Yamada T, et
al: Phase II study of the tetrahydropyranyl
adriamycin-cyclophosphamide, vincristine, and prednisolone regimen
combined with rituximab as first-line treatment for elderly
patients with diffuse large B-cell lymphoma. Leuk Lymphoma.
52:629–634. 2011.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Hara T, Yoshikawa T, Goto H, Sawada M,
Yamada T, Fukuno K, Kasahara S, Shibata Y, Matsumoto T, Mabuchi R,
et al: R-THP-COP versus R-CHOP in patients younger than 70 years
with untreated diffuse large B-cell lymphoma: A randomized,
open-label, non-inferiority phase 3 trial. Hematol Oncol.
36:638–644. 2018.PubMed/NCBI View
Article : Google Scholar
|
|
38
|
Sawada M, Tsurumi H, Yamada T, Hara T,
Fukuno K, Goto H, Shimizu M, Kasahara S, Yoshikawa T, Kanemura N,
et al: A prospective study of P-IMVP-16/CBDCA: A novel salvage
chemotherapy for patients with aggressive non-Hodgkin's lymphoma
who had previously received CHOP therapy as first-line
chemotherapy. Eur J Haematol. 68:354–361. 2002.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Matsumoto T, Hara T, Shibata Y, Nakamura
N, Nakamura H, Ninomiya S, Kitagawa J, Kanemura N, Goto N, Kito Y,
et al: A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of
rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide,
and carboplatin for patients with diffuse large B cell lymphoma who
had previously received R-CHOP therapy as first-line chemotherapy.
Hematol Oncol. 35:288–295. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
40
|
Cheson BD, Pfistner B, Juweid ME, Gascoyne
RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca
E, et al: Revised response criteria for malignant lymphoma. J Clin
Oncol. 25:579–586. 2007.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Kaplan EL and Meier P: Nonparametric
estimation from incomplete observations. J Am Stat Assoc.
53:457–481. 1958.
|
|
42
|
Valko M, Leibfritz D, Moncol J, Cronin MT,
Mazur M and Telser J: Free radicals and antioxidants in normal
physiological functions and human disease. Int J Biochem Cell Biol.
39:44–84. 2007.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Bjelland S and Seeberg E: Mutagenicity,
toxicity and repair of DNA base damage induced by oxidation. Mutat
Res. 531:37–80. 2003.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Kryston TB, Georgiev AB, Pissis P and
Georgakilas AG: Role of oxidative stress and DNA damage in human
carcinogenesis. Mutat Res. 711:193–201. 2011.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Schöttker B, Saum KU, Jansen EH, Boffetta
P, Trichopoulou A, Holleczek B, Dieffenbach AK and Brenner H:
Oxidative stress markers and all-cause mortality at older age: A
population-based cohort study. J Gerontol A Biol Sci Med Sci.
70:518–524. 2015.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Schöttker B, Brenner H, Jansen EH,
Gardiner J, Peasey A, Kubínová R, Pająk A, Topor-Madry R,
Tamosiunas A, Saum KU, et al: Evidence for the free
radical/oxidative stress theory of ageing from the CHANCES
consortium: A meta-analysis of individual participant data. BMC
Med. 13(300)2015.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Lan Q, Zheng T, Shen M, Zhang Y, Wang SS,
Zahm SH, Holford TR, Leaderer B, Boyle P and Chanock S: Genetic
polymorphisms in the oxidative stress pathway and susceptibility to
non-Hodgkin lymphoma. Hum Genet. 121:161–168. 2007.PubMed/NCBI View Article : Google Scholar
|
